213 related articles for article (PubMed ID: 1356349)
1. Animal models for the study of human immunodeficiency virus infections.
Letvin NL
Curr Opin Immunol; 1992 Aug; 4(4):481-5. PubMed ID: 1356349
[TBL] [Abstract][Full Text] [Related]
2. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
[TBL] [Abstract][Full Text] [Related]
3. Development of prophylactic AIDS vaccines: the current state of affairs.
Hanke T
Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
[TBL] [Abstract][Full Text] [Related]
4. Progress toward an HIV vaccine.
Letvin NL
Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510
[TBL] [Abstract][Full Text] [Related]
5. Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine.
Yamamoto JK; Pu R; Sato E; Hohdatsu T
AIDS; 2007 Mar; 21(5):547-63. PubMed ID: 17314517
[No Abstract] [Full Text] [Related]
6. Potential pitfalls on the road to an effective HIV vaccine.
Schwartz DH
Immunol Today; 1994 Feb; 15(2):54-7. PubMed ID: 7908803
[TBL] [Abstract][Full Text] [Related]
7. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
8. HIV immunotherapy comes of age: implications for prevention, treatment and cure.
Routy JP; Mehraj V; Cao W
Expert Rev Clin Immunol; 2016; 12(2):91-4. PubMed ID: 26629806
[TBL] [Abstract][Full Text] [Related]
9. Toward an understanding of the correlates of protective immunity to HIV infection.
Haynes BF; Pantaleo G; Fauci AS
Science; 1996 Jan; 271(5247):324-8. PubMed ID: 8553066
[TBL] [Abstract][Full Text] [Related]
10. The critical role of CD4(+) T-cell help in immunity to HIV.
Heeney JL
Vaccine; 2002 May; 20(15):1961-3. PubMed ID: 11983254
[TBL] [Abstract][Full Text] [Related]
11. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL
Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923
[TBL] [Abstract][Full Text] [Related]
12. Protection from HIV infection or AIDS?
Miedema F; Meyaard L; Klein MR
Science; 1993 Nov; 262(5136):1074-6. PubMed ID: 8235627
[No Abstract] [Full Text] [Related]
13. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
Wrin T; Nunberg JH
AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
[No Abstract] [Full Text] [Related]
14. Nonhuman primate models for HIV vaccine development.
Letvin NL
Immunodefic Rev; 1992; 3(3):247-60. PubMed ID: 1510838
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
16. A strategy for prophylactic vaccination against HIV.
Salk J; Bretscher PA; Salk PL; Clerici M; Shearer GM
Science; 1993 May; 260(5112):1270-2. PubMed ID: 8098553
[No Abstract] [Full Text] [Related]
17. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
[TBL] [Abstract][Full Text] [Related]
18. Prospects for vaccine protection against HIV-1 infection and AIDS.
Letvin NL; Barouch DH; Montefiori DC
Annu Rev Immunol; 2002; 20():73-99. PubMed ID: 11861598
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus antibodies and the vaccine problem.
Chiodi F; Weiss RA
J Intern Med; 2014 May; 275(5):444-55. PubMed ID: 24581142
[TBL] [Abstract][Full Text] [Related]
20. Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits.
Hewer R; Meyer D
Mol Immunol; 2003 Oct; 40(6):327-35. PubMed ID: 14522014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
